

INDEX TO VOLUME 26

AUTHOR INDEX


- Abdel-Azim, S., 193
 Ali, M.Y., 65
 Allonen, H., 29, 113
 Andersch, B., 211
 Anderson, N.B., 229
 Andersen, R.F., 229
 Araki, R., 221
 Assandri, A., 165
 Åstedt, B., 147
 Aznar, R., 475
 Bamji, M.S., 607
 Barthololeyns, J., 535
 Bernstein, G.S., 443
 Bernstein, R., 443
 Beyler, S.A., 137
 Bouclier, M., 535
 Bredesgaard, P., 229
 Bremser, H.-J., 303
 Brenner, P.F., 261
 Burns, J.W., 521
 Cameron, E.D., 121
 Casslén, B., 147
 Cekan, S.Z., 545
 Channing, C.P., 617
 Clark, V.A., 443
 Coan, C., 443
 Coulson, A.H., 443
 Covey, D.C., 595
 Craig, S., 347
 Cullberg, G., 229
 Díaz, J., 221
 Díaz, M.M., 221
 Diezfalusy, E., 545, 567
 El-Sharkawy, M.M., 65, 75
 Elstein, M., 121
 Ernerot, H., 229
 Fanøe, E., 229
 Farag, R.S., 645
 Fathalla, M.F., 65, 75
 Faúndes, A., 221
 Fayad, M., 193
 Fotherby, K., 51
 Fraser, I.S., 321, 361, 373, 389
 Frezieres, R., 443
 Friel, P., 521
 Fylling, P., 229, 279
 Gallegos, A.J., 475
 Galliani, G., 165
 Gamble, V.M., 97
 Ganguly, T., 635
 Ghaneimah, S.A., 65, 75
 Giridharan, N., 607
 Glinsukon, T., 625
 Goodpasture, J.C., 521
 Graham, S., 323, 373
 Grant, A.M., 165
 Graves, Z.R., 59
 Haack-Sørensen, P.-E., 229
 Hahn, D.W., 617
 Hammad, W.A., 65, 75

CONTRACEPTION

- Heikkilä, M., 245, 465
 Hepburn, S., 347
 Hofman, A., 205
 Hümpel, M., 83
 Hurst, P.R., 97, 159
 Ibrahim, M.H., 645
 Johannisson, E., 567
 Kilzer, L.H., 443
 Klottrup, P., 229
 Koetsawang, S., 51
 Kuhl, H., 303
 Kurkulos, M., 59
 Lähteenmäki, P., 245
 Lancini, G., 165
 Landgren, B.-M., 545, 567
 Lauersen, N.H., 59
 Laurence, K.A., 595
 Leavesley, G., 417
 Lee, C.-P., 515
 Leeds, L., 59
 Leepipatpaiboon, S., 487
 Lerner, L.J., 165
 Liao, W.C., 65, 75
 Lindholm, K., 147
 Lozano, M., 475
 Luukkainen, T., 29, 113, 245, 465
 Marrs, R.P., 261
 Masironi, B., 567
 McCafferty, E., 121
 Milsom, I., 211
 Mishell, D.R., Jr., 261
 Nagib, A.M., 645
 Nagui, A.R., 193
 Nakamura, R.M., 443
 Needleman, S.W., 317
 Nielsen, N.-C., 29, 113
 Nillius, S.J., 457
 Nock, P.E., 165
 Nuttall, I.D., 121
 Nygren, K.-G., 29, 113
 Nylander, P., 465
 Ohlsson, K., 147
 Omodei-Salè, A., 165
 Pakrashi, A., 635
 Parks, W.M., 317
 Pastene, L., 221
 Pedersen, J.H., 229
 Pedrón, N., 475
 Peplow, P.V., 97, 159
 Peugvicha, P., 625
 Phillips, A., 617
 Piyachaturawat, P., 625
 Porter, J., 417
 Pyörälä, T., 29, 113
 Robins, J., 285
 Roy, S., 261
 Russowsky, M., 41
 Saksena, S.K., 181
 Salim, T.H., 65, 75
 Samsioe, G., 229
 Sandager, T., 229
 Sankaram, A.V.B., 607
 Sartoretto, J.N., 41
 Schmidt, F., 295
 Seth, J., 121
 Shaaban, M.M., 65, 75
 Shaarawy, M., 193
 Shi, S., 545
 Simecock, B.W., 323
 Siriwongse, T., 487
 Skarin, G., 457
 Smith, G.C., 443
 Smith, S.C., 65, 75
 Snidvongs, W., 487

CONTRACEPTION

- Surrago, E.J., 285
Swyer, G.I.M., 23
Tang, F., 515
Tantayaporn, P., 487
Tatum, H.J., 295
Taubert, H.-D., 303
Thiery, M., 295, 505
Tsang, A.Y.F., 515
van Vliet, H.C.A.M., 205
Vermeulen, A., 505
von Dadelszen, P., 159
Wang, E., 545
Weisberg, E., 361, 389
Wheeler, R., 521
WHO Task Force on Female Sterilization, 587
WHO Task Force on Intrauterine Devices for Fertility Regulation, 1
Wide, L., 457
Wong, P.Y.D., 515
Youssef, A.M., 645
Zaneveld, L.J.D., 137, 521



INDEX TO VOLUME 26

SUBJECT INDEX

- Abortifacient effect,
 - D-Ser(TBU)⁶-EA¹⁰-LRH, 457
 - piperine (mouse), 625
- Abortifacient results, 9-deoxo-16,16-dimethyl-9-methylene PGE₂ vaginal suppository
 - for termination of early gestation, 261
- Abortion, effects on subsequent reproduction, 389
- Abortion rate, PGE₂ vaginal suppository for midtrimester pregnancy termination, 285
- Absorption in animals, norethisterone, 83
- Acid phosphatase activity in uterus, effect of aristolic acid (mouse), 635
- Aerosin inhibitors, antifertility activity (mouse), 137
- Acute toxicity, 4-methylumbelliferone-4-guanidinobenzoate (mouse), 137
- Advantages, using spermicides with barriers, 347
- Albumin/globulin ratio, effect of antibilharzial and contraceptive drugs (rat), 645
- Alkaline phosphatase,
 - effect of antibilharzial and contraceptive drugs (rat), 645
 - effect of ethinyl estradiol + levonorgestrel in women with active schistosomiasis, 75
 - effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65
- Alkaline phosphatase activity in uterus, effect of aristolic acid (mouse), 635
- Alpha-1 antitrypsin,
 - effect of ethinyl estradiol + levonorgestrel in women with active schistosomiasis, 75
 - effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65
- 4-Aminobenzamidine, antifertility activity (mouse), 137
- Anaesthesia, effect on duration of operation and length of incision for post-partum sterilization, 495
- Antibilharzial drugs and ethinyl oestradiol + d-norgestrel, effect on liver function (rat), 645
- Antibody response when immunized with β -hCG coupled to tetanus toxoid, effect of carrier preimmunization (rabbit), 595
- Antifertility activity,
 - DL III (baboon), 165
 - piperine (mouse), 625
 - systemically administered proteinase (acrosin) inhibitors (mouse), 137

CONTRACEPTION

- Antifibrinolytic agents, release rate from ethylene-vinyl acetate matrix, 521
- Aristollic acid, effect on uterine phosphatase levels during early pregnancy (mouse), 635
- Aristollic acid + progesterone, effect on uterine phosphatase levels during early pregnancy (mouse), 635
- Barrier methods, fertility following discontinuation, 389
- Barrier methods and spermicides, use in disabled people, 417
- Barrier methods of contraception,
 effectiveness with and without spermicide, 347
 use among young Swedish women, 211
- Benzamidine, antifertility activity (mouse), 137
- Bilirubin,
 effect of ethinyl estradiol + levonorgestrel in women with active schistosomiasis, 75
 effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65
- Bioavailability in animals, norethisterone, 83
- Biotransformation and pharmacokinetics in animals, norethisterone, 83
- Bleeding and spotting,
 levonorgestrel-releasing IUD, 245, 465
 Nova-T, 245, 465
- Bleeding pattern,
 effect of ethinyl estradiol + levonorgestrel, 121, 545
 effect of levonorgestrel-releasing IUD, 465
 effect of Nova-T, 465
 effect of vaginal device releasing levonorgestrel, 567
 effect of vaginal device releasing norethisterone, 567
- Cadmium chloride, effect on ovulation, egg transport and pregnancy (rabbit), 181
- Carcinogenesis, progestogen-only mini-pill, 373
- Carrier preimmunization, effect on neutralizing antibody response when immunized with β -hCG coupled to tetanus toxoid (rabbit), 595
- Catechol estrogens and thrombosis, 317
- Catechol-O-methyltransferase, effect of gossypol (rat), 515
- Catechol-O-methyltransferase inhibition by gossypol, effect of plasma proteins (rat), 515
- Cavity Rim cap, studies of cervical caps, 443
- Ceruloplasmin,
 effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
 effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65

CONTRACEPTION

- Cervical barrier,
 - effectiveness, 347
 - instructions for use by family planning authorities, 347
- Cervical caps, vaginal lesions associated with use, 443
- Cervical mucus, effect of ethinyl estradiol + levonorgestrel, 121
- Cervical priming, 15-ME-PGF_{2α} prior to IUD insertion, 59
- Choice of device, IUD use in nulliparous women, 323
- Cholesterol,
 - effect of ethinylestradiol + desogestrel, 229
 - effect of levonorgestrel followed by ethinyl estradiol + norgestrel, 41
 - effect of triphasic ethinylestradiol + l-norgestrel, 505
 - effect of triphasic ethinylestradiol + levonorgestrel, 229
- Clinical study, Lippes loop C and T-Cu 380A, 221
- Closure,
 - levonorgestrel-releasing IUD, 245
 - Nova-T, 245
- Combined oestrogen-progestogen oral contraceptives, fertility following discontinuation, 389
- Comparative study,
 - culdoscopy and minilaparotomy for surgical contraception, 587
 - Nova T and Copper T 200, 29
- Comparative trial, interval IUD insertion in parous women, 1
- Complication,
 - 9-deoxo-16,16-dimethyl-9-methylene PGE₂ vaginal suppository for termination of early gestation, 261
 - IUD use in nulliparous women, 323
 - PGE₂ vaginal suppository for midtrimester pregnancy termination, 285
- Complications and complaints,
 - culdoscopy for surgical contraception, 587
 - mini-incision for post-partum sterilization, 495
 - minilaparotomy for surgical contraception, 587
- Condition of newborn,
 - pregnancy after removal of Copper T 200, 113
 - pregnancy after removal of Nova T, 113
- Condom,
 - effectiveness, 347
 - instructions for use by family planning authorities, 347

CONTRACEPTION

- Continuation rate,
 - Lippes loop C, 221
 - progestogen-only mini-pill, 373
 - T-Cu 380A, 221
- Contraception and pregnancy, among young Swedish women, 211
- Contraception in disabled people, 417
- Contraceptive counselling for disabled people, 417
- Contraception profile, DL III (baboon), 165
- Conversion of precursors into norethisterone in animals, 83
- Copper 7,
 - effect on hemoglobin levels, 475
 - menstrual blood loss estimates, 475
 - randomized multicentre comparative trial, 1
- Copper dissolution rate, effect of mineral deposits on TCu220C, 295
- Copper loss from TCu220C, 295
- Copper T 200,
 - comparative study, 29
 - return of fertility after removal, 113
- Cortisol,
 - effect of ethynodiol diacetate + mestranol, 193
 - effect of triphasic ethinylestradiol + 1-norgestrel, 505
- Cortisol metabolism and correlation to depression, ethynodiol diacetate + mestranol, 193
- Culdocopy and minilaparotomy, comparative study for surgical contraception, 587
- Cumulative net probabilities of discontinuation, randomized multicentre trial
 - of IUDs, 1
- Cumulative probability of pregnancy, after removal of IUD, 113
- Cumulative rates, comparative study of Nova T and Copper T 200, 29
- Cycle control,
 - ethinylestradiol + desogestrel, 229
 - levonorgestrel followed by ethinyl estradiol + norgestrel, 41
 - triphasic ethinylestradiol + levonorgestrel, 229
- Cycle, effect of porcine follicular fluid (rat), 617
- D-Ser(TBU)⁶-EA¹⁰-LRH, abortifacient effect, 457
- Dehydroepiandrosterone, effect of triphasic ethinylestradiol + 1-norgestrel, 505
- Dehydroepiandrosterone sulphate, effect of triphasic ethinylestradiol + 1-norgestrel, 505

- Delay of Menses Test, 23
- Delayed labor, effect of piperine (mouse), 625
- 9-Deoxy-16,16-dimethyl-9-methylene PGE₂ vaginal suppository, termination of early gestation, 261
- Depot-medroxyprogesterone acetate,
 - effect on progesterone levels when administered on various cycle days, 487
 - fertility following discontinuation, 389
 - use in disabled people, 417
- Depression and serotonin metabolism, effect of ethynodiol diacetate + mestranol, 193
- Development and evaluation of inhibitor-releasing matrix for IUDs, 521
- Disability and reproduction, 417
- Disabled people, sexuality, fertility and contraception, 417
- Disadvantages, using spermicides with barriers, 347
- Discontinuation,
 - ethinyloestradiol + desogestrel, 229
 - levonorgestrel followed by ethinyl estradiol + norgestrel, 41
 - randomized multicentre trial of IUDs, 1
 - triphasic ethinyloestradiol + levonorgestrel, 229
- Discontinuation of oral contraception, reasons among young Swedish women, 211
- Dissolution rate of copper, effect of mineral deposits on TCu220C, 295
- DL III (3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4 triazole)
- DL III plasma levels, after administration (baboon), 165
- Early gestation termination, 9-deoxy-16,16-dimethyl-9-methylene PGE₂ vaginal suppository, 261
- Early pregnancy, effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 457
- Ectopic pregnancy,
 - after sterilization reversal, 361
 - following contraceptive use, 389
- Effectiveness, barrier methods of contraception with and without spermicide, 347
- Efficacy,
 - administration of Sulprostone for termination of second trimester pregnancy, 279
 - ethinyloestradiol + desogestrel, 229
 - progestogen-only mini-pill, 373
 - triphasic ethinyloestradiol + levonorgestrel, 229
- Egg transport, effect of cadmium chloride (rabbit), 181
- Endometrial effect, vaginal device releasing levonorgestrel, 567
- Enterohepatic circulation in animals, norethisterone, 83

CONTRACEPTION

- Estradiol, effect on prostacyclin release, 317
- Estradiol level,
 effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 457
 effect of ethinyl estradiol + levonorgestrel, 121, 545
 effect of levonorgestrel-releasing IUD, 245
 effect of vaginal device releasing levonorgestrel, 567
- Ethinyl estradiol + ethynodiol diacetate, delay of menses, 23
- Ethinylestradiol + l-norgestrel triphasic, metabolic effects, 505
- Ethinyl estradiol + levonorgestrel,
 effect on pituitary-ovarian function during normal tablet-taking, 121
 effect on pituitary-ovarian function when tablets are missed, 121
 hormonal consequences of missing the pill, 545
 liver function tests and serum proteins in women with active schistosomiasis, 75
 liver function tests and serum proteins in women with past viral hepatitis, 65
- Ethinyl estradiol + norethindrone, delay of menses, 23
- Ethinyl estradiol + norethindrone acetate, delay of menses, 23
- Ethinyl estradiol + norgestrel, delay of menses, 23
- Ethinyl estradiol + norgestrel following levonorgestrel, new approach to oral
 contraception, 41
- Ethinyl estradiol level, effect of ethinyl estradiol + levonorgestrel, 121
- Ethinylestradiol + desogestrel, efficacy, effect on serum proteins and lipid
 metabolism, 229
- Ethinyl oestradiol + d-norgestrel and antibilharzial drugs, effect on liver function
 (rat), 645
- Ethinylestradiol + levonorgestrel triphasic, efficacy, effect on serum proteins
 and lipid metabolism, 229
- Ethylene-vinyl acetate, use as inhibitor-releasing matrix for IUDs, 521
- 3-(2-Ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4 triazole (DL III),
 contragestational profile (baboon), 165
 kinetic profile (baboon), 165
 non-hormonal antifertility agent (baboon), 165
- Ethynodiol diacetate + mestranol, effect on serotonin metabolism and depression, 193
- Evaluation of inhibitor-releasing matrix for IUDs, 521
- Event rates, IUD use in nulliparous women, 323
- Events during four years of use,
 Copper T 200, 29
 Nova T, 29

Excretion in animals, norethisterone, 83

Expulsion,

Copper 7, 1

Copper T 200, 29

IUD use in nulliparous women, 323

levonorgestrel-releasing IUD, 245

Lippes loop C, 221

Lippes Loop D, 1

Nova T, 29, 245

randomized multicentre trial of IUDs, 1

TCu220C, 1

T-Cu 380A, 221

Failure rate, PGE₂ vaginal suppository for midtrimester pregnancy termination, 285

Family planning services for disabled people, 417

Ferritin concentration,

levonorgestrel-releasing IUD, 465

Nova T, 465

Fertility,

after abortion induced by DL 111 (baboon), 165

after removal of IUD, 113

Fertility following discontinuation, review of different methods of fertility control, 389

Fertility following reversal of sterilization, 361

Fertility in disabled people, 417

Fertility post-pill, progestogen-only mini-pill, 373

Follitropin (FSH)

FSH (follicle stimulating hormone or follitropin)

FSH level,

effect of ethinyl estradiol + levonorgestrel, 121, 545

effect of levonorgestrel-releasing IUD, 245

Future fertility, IUD use in nulliparous women, 323

Gestation, effect of α -monofluoromethyl histidine (mouse), 535

Glucose, effect of triphasic ethinylestradiol + l-norgestrel, 505

Glutamic-oxaloacetic transaminase, effect of antibilharzial and contraceptive drugs (rat), 645

Glutamic-pyruvic transaminase, effect of antibilharzial and contraceptive drugs (rat), 645

Gonadotrophin-releasing hormone analogues, fertility following discontinuation, 389

CONTRACEPTION

Gossypol,

- effect on catechol-O-methyltransferase (rat), 515
- effect on testis cytosolic lactic dehydrogenase-X activity (rat), 607
- purification procedure, 607

Gossypol inhibition of catechol-O-methyltransferase, effect of plasma proteins (rat), 515

Haptoglobin,

- effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
- effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65

HCG (human chorionic gonadotropin)

- β -hCG coupled to tetanus toxoid immunization, effect of carrier preimmunization on neutralizing antibody response (rabbit), 595

HCG level, effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 457

- β -hCG level, effect of 9-deoxy-16,16-dimethyl-9-methylene PGE₂, 261

HDL (high-density lipoproteins)

HDL-cholesterol,

- effect of ethinylestradiol + desogestrel, 229
- effect of triphasic ethinylestradiol + 1-norgestrel, 505
- effect of triphasic ethinylestradiol + levonorgestrel, 229

Hematological changes,

- levonorgestrel-releasing IUD, 465
- Nova-T, 465

Hemoglobin level,

- Cu-7, 475
- Multiload-250, 475

High-density lipoproteins (HDL), effect of levonorgestrel followed by ethinyl estradiol + norgestrel, 41

Histidine decarboxylase activity, effect of α -monofluoromethyl histidine in foeti and newborn (mouse), 535

Histamine content, effect of α -monofluoromethyl histidine in foeti and newborn (mouse), 535

Histological examination of liver,

- effect of metrifphonate (rat), 645
- effect of oxamniquine (rat), 645

Hormonal consequences of "missing the pill", ethinyl estradiol + levonorgestrel, 545

17-Hydroxycorticoid, effect of ethynodiol diacetate + mestranol, 193

2-Hydroxyestradiol, effect on prostacyclin release, 317

5-Hydroxyindole acetic acid, effect of ethynodiol diacetate + mestranol, 193

5-Hydroxyindoles, effect of ethynodiol diacetate + mestranol, 193

CONTRACEPTION

- 5-Hydroxytryptamine, effect of ethynodiol diacetate + mestranol, 193
- Immediate postabortal insertion,
 - levonorgestrel-releasing IUD, 245
 - Nova-T, 245
- Immediate post-insertion complications, IUD use in nulliparous women, 323
- Immunization with β -hCG coupled to tetanus toxoid, effect of carrier preimmunization on neutralizing antibody response (rabbit), 595
- Immunological methods of contraception, fertility following discontinuation, 389
- Implantation,
 - effect of indomethacin-loaded IUD (rat), 97
 - effect of piperine (mouse), 625
- Indomethacin-loaded IUD, effect on preimplantation embryo and implantation (rat), 97
- Indomethacin-loaded silastic rods, effect on retention of IUD (rat), 159
- Infertility following abortion, 389
- Infertility following hormonal contraceptive use, 389
- Informed consent, fertility control services for disabled people, 417
- Inhibition of catechol-O-methyltransferase by gossypol, effect of plasma proteins (rat) 515
- Inhibition of testis cytosolic lactic dehydrogenase-X activity, effect of gossypol (rat), 607
- Inhibitor-releasing matrix for IUDs, development and evaluation, 521
- Initiation to abortion time,
 - 9-deoxo-16,16-dimethyl-9-methylene PGE₂ vaginal suppository for termination of early gestation, 261
 - PGE₂ vaginal suppository for midtrimester pregnancy termination, 285
- Injectable contraception, use in disabled people, 417
- Injectable contraceptive,
 - depo-medroxyprogesterone acetate, 487
 - medroxyprogesterone acetate, 51
 - norethisterone oenanthate, 51
- Injectable hormonal contraceptives, fertility following discontinuation, 389
- Insertion of IUD, prior cervical priming with 15-ME-PGF_{2 α} , 59
- Insertion techniques, IUD use in nulliparous women, 323
- Instructions for use by family planning authorities,
 - cervical barriers, 347
 - condoms, 347
 - spermicides, 347

CONTRACEPTION

- Insulin, effect of triphasic ethinylestradiol + 1-norgestrel, 505
- Intrauterine delivery of indomethacin from a silastic device (rat), 97
- Intrauterine device (IUD),
 - Copper 7, 1, 475
 - Copper T 200, 29, 113
 - development and evaluation of inhibitor-releasing matrix, 521
 - effect of indomethacin-loaded silastic rods on retention (rat), 159
 - fertility following discontinuation, 389
 - indomethacin-loaded silastic rods (rat), 159
 - levonorgestrel-releasing, 245, 465
 - Lippes loop C, 221
 - Lippes Loop D, 1
 - Multiload-250, 475
 - Nova T, 29, 113, 245, 465
 - release of proteolytic enzymes from attached leucocytes, 147
 - review of use in nulliparous women, 323
 - silastic device incorporating indomethacin (rat), 97
 - TCu 200, 147
 - TCu200C, 1, 295
 - T-CU 380A, 221
 - tranexamic acid-releasing, 521
 - Trasylol-releasing, 521
 - use among young Swedish women, 211
 - use in disabled people, 417
- In vitro investigations in animals, norethisterone, 83
- Iron stores,
 - effect of levonorgestrel-releasing IUD, 465
 - effect of Nova-T, 465
- IUD (intrauterine device)
- IUD incorporating indomethacin, effect on preimplantation embryo and implantation (rat), 97
- IUD insertion, prior cervical priming with 15-ME-PGF_{2α}, 59
- Kinetic profile, DL III (baboon), 165
- Kinetics and biotransformation in animals, norethisterone, 83
- Lactic dehydrogenase-X activity of testis, effect of gossypol (rat) 607
- Lactation, effect of progestogen-only mini-pill, 373
- Laminaria, continuous oxytocin infusion and PGE₂ vaginal suppository, midtrimester pregnancy termination, 285

- Laminaria and PGE₂ vaginal suppository, midtrimester pregnancy termination, 285
- LDL (low density lipoproteins)
- LDL-cholesterol, effect of triphasic ethinylestradiol + l-norgestrel, 505
- Lesions observed with Vimule cap, studies of cervical caps, 443
- Leucocytes attached to IUDs, release of proteolytic enzymes, 147
- Levonorgestrel,
 - pharmacokinetic and pharmacodynamic investigations, 567
 - review of progestogen-only mini-pill, 373
- Levonorgestrel followed by ethinyl estradiol + norgestrel, new approach to oral contraception, 41
- Levonorgestrel level,
 - effect of ethinyl estradiol + levonorgestrel, 545
 - effect of levonorgestrel-releasing IUD, 245
 - effect of vaginal device releasing levonorgestrel, 567
- Levonorgestrel-releasing IUD,
 - body iron stores and patterns of bleeding, 465
 - hematologic changes, 465
 - immediate postabortal insertion, 245
- Levonorgestrel vaginal delivery system,
 - endometrial effect, 567
 - ovarian effect, 567
- LH (luteinizing hormone or lutropin)
- LH levels,
 - effect of ethinyl estradiol + levonorgestrel, 121, 545
 - effect of levonorgestrel-releasing IUD, 245
- Lipid metabolism,
 - effect of ethinyloestradiol + desogestrel, 229
 - effect of triphasic ethinyloestradiol + levonorgestrel, 229
- Lippes loop C, randomized clinical study, 221
- Lippes Loop D, randomized multicentre comparative trial, 1
- Liver cells,
 - effect of metrifphonate (rat), 645
 - effect of oxamniquine (rat), 645
- Liver function, effect of antibilharzial and contraceptive drugs (rats) 645
- Liver function tests,
 - effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
 - effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65

CONTRACEPTION

LRH (luteinizing hormone-releasing hormone)

LRH agonist, D-Ser(TBU)⁶-EA¹⁰-LRH, 457

Lutropin (LH)

Lynestrenol ingestion, serum levels and pharmacokinetics of norethisterone, 303

Male methods of hormonal contraception, fertility following discontinuation, 389

Margin of safety of acrosin inhibitors with respect to fertility (mouse), 137

Mating, effect of porcine follicular fluid (rat), 617

15-ME-PGF_{2α} (15(S)-15-prostaglandin F_{2α} methyl ester)

15-ME-PGF_{2α} vaginal suppository, cervical priming prior to IUD insertion, 59

Mechanisms of action, progestogen-only mini-pill, 373

Medroxyprogesterone acetate, metabolism in obese and thin women, 51

Medroxyprogesterone acetate level, after injection in obese and thin women, 51

Menstrual blood loss,

Cu-7, 475

Multiloal-250, 475

Menstrual cycle, after abortion induced by DL III (baboon), 165

Menstrual cycle changes, progestogen-only mini-pill, 373

Menstrual cycle restoration,

immediate postabortal insertion of levonorgestrel-releasing IUD, 245

immediate postabortal insertion of Nova-T, 245

Menstrual cycle stage, effect on serum levels and pharmacokinetics of norethisterone

after ingestion of lynestrenol, 303

Menstrual hygiene in mental and physical disability, 417

Metabolic effect,

progestogen-only mini-pill, 373

triphasic ethinylestradiol + 1-norgestrel, 505

Metabolism of injectable contraceptives in obese and thin women, 51

4-Methylumbelliferone-4-guanidinobenzoate,

acute toxicity (mouse), 137

antifertility activity (mouse), 137

Metriphonate,

effect on liver cells (rat), 645

effect on liver function (rat), 645

Microsurgery, role in reversal of tubal sterilization, 361

Midtrimester pregnancy termination, PGE₂ vaginal suppository, 287

Mineral deposits on TCu220C, effect on copper dissolution rate, 295

Mini-incision for post-partum sterilization, 495

Minilaparotomy and culdoscopy, comparative study for surgical contraception, 585

- Missed tablets of ethinyl estradiol + levonorgestrel,
 - effect on pituitary-ovarian function, 121
 - hormonal consequences, 545
- α -Monofluoromethyl histidine, effect of gestation (mouse), 535
- Multiload-250,
 - effect on hemoglobin levels, 475
 - menstrual blood loss estimates, 475
- National Medical Task Force of the Australian Federation of Family Planning Associations, 321
- Natural methods of contraception, use in disabled people, 417
- 4-Nitrophenyl-4-guanidinobenzoate, antifertility activity (mouse), 137
- Non-hormonal antifertility agent, DL III (baboon), 165
- Norethisterone,
 - pharmacokinetics and biotransformation in animals, 83
 - review of progestogen-only mini-pill, 373
- Norethisterone level,
 - after ingestion of lynestrenol, 303
 - after injection in obese and thin women, 51
 - following administration of norethisterone, 303
- Norethisterone levels in animals, after norethisterone administration, 83
- Norethisterone minipill, ovarian effect, 567
- Norethisterone oenanthate,
 - fertility following discontinuation, 389
 - metabolism in obese and thin women, 51
- Norethisterone pharmacokinetics, after ingestion of lynestrenol, 303
- Norethisterone vaginal delivery system, ovarian effect, 567
- 1-Norgestrel level, effect of ethinyl estradiol + levonorgestrel, 121
- Nova T,
 - body iron stores and patterns of bleeding, 465
 - comparative study, 29
 - hematological changes, 465
 - immediate postabortal insertion, 245
 - return of fertility after removal, 113
- Nulliparous women, review of use of IUD, 323
- Obese and thin women, metabolism of injectable contraceptives, 51

CONTRACEPTION

- Oestrogen-progesterone combination injectable preparations, fertility following discontinuation, 389
- Operator experience, IUD insertion in nulliparous women, 323
- Oral contraception, use in disabled people, 417
- Oral contraceptive,
 - ethinyl estradiol + ethynodiol diacetate, 23
 - ethinyl estradiol + levonorgestrel, 67, 75, 121, 545
 - ethinyl estradiol + norethindrone, 23
 - ethinyl estradiol + norethindrone acetate, 23
 - ethinyl estradiol + norgestrel, 23
 - ethinyloestradiol + desogestrel, 229
 - ethinyl oestradiol + d-norgestrel (rat), 645
 - ethynodiol diacetate + mestranol, 193
 - levonorgestrel followed by ethinyl estradiol + noregestrel, 41
 - review of progestogen-only mini-pills, 373
 - trends in use among Dutch young women, 205
 - triphasic ethinylestradiol + l-norgestrel, 505
 - triphasic esthinyloestradiol + levonorgestrel, 229
 - use among young Swedish women, 211
- Outcome of pregnancy,
 - after removal of Copper T 200, 113
 - after removal of Nova T, 113
 - among young Swedish women, 211
- Ovarian effect,
 - aristollic acid during early pregnancy (mouse), 635
 - norethisterone minipill, 567
 - vaginal device releasing levonorgestrel, 567
 - vaginal device releasing norethisteorne, 567
- Ovarian function, influence of tubal sterilization, 361
- Ovulation,
 - effect of cadmium chloride (rabbit), 181
 - effect of porcine follicular fluid (rat), 617
- Oxamniquine,
 - effect on liver cells (rat), 645
 - effect on liver function (rat), 645
- 17-Oxosteroid, effect of ethynodiol diacetate + mestranol, 193

- Oxytocin infusion, laminaria and PGE₂ vaginal suppository, midtrimester pregnancy termination, 285
- Parous women, randomized multicentre trial of IUDs, 1
- Pelvic inflammatory disease, IUD use in nulliparous women, 323
- Perforation,
 - Copper 7, 1
 - Lippes Loop D, 1
 - randomized multicentre trial of IUDs, 1
 - TCu220C, 1
- PG (prostaglandin)
- PGE₂ vaginal suppository,
 - laminaria and continuous oxytocin infusion, midtrimester pregnancy termination, 285
 - midtrimester pregnancy termination, 285
- PGE₂ vaginal suppository and laminaria, midtrimester pregnancy termination, 285
- Pharmacokinetics,
 - DL III (baboon), 165
 - norethisterone, 303
 - norethisterone after ingestion of lynestrenol, 303
- Pharmacokinetic and pharmacodynamic investigation, vaginal device releasing levonorgestrel, 567
- Pharmacokinetics and biotransformation in animals, norethisterone, 83
- 16-Phenoxy- ω -tetranor-PGE₂-methylsulfonamide (Sulprostone), termination of second trimester pregnancy, 279
- Phosphatase levels, effect of aristolic acid during early pregnancy (mouse), 635
- Physical disability and sexuality, 417
- Piperine, antifertility activity (mouse), 625
- Pituitary-ovarian function,
 - effect of ethinyl estradiol + levonorgestrel during normal tablet-taking, 121
 - effect of ethinyl estradiol + levonorgestrel when tablets are missed, 121
- Porcine follicular fluid,
 - effect of post-coital treatment on pregnancy (rat), 617
 - effect on ovulation, mating and pregnancy (rat), 617
- Postcoital antifertility effect, piperine (mouse), 625
- Post-coital treatment with porcine follicular fluid, effect on pregnancy (rat), 617
- Post-insertion instructions, IUD use in nulliparous women, 323
- Post-partum sterilization, mini-incision, 495
- Potency of progestogens in oral contraceptives, Delay of Menses Test, 23

CONTRACEPTION

Precursor conversions into norethisterone in animals, 83

Pregnancy,

Copper 7, 1

Copper T 200, 29

effect of cadmium chloride (rabbit), 181

effect of porcine follicular fluid (rat), 617

IUD use in nulliparous women, 323

levonorgestrel followed by ethinyl estradiol + norgestrel, 41

levonorgestrel-releasing IUD, 245

Lippes loop C, 221

Lippes Loop D, 1

Nova T, 29, 245

randomized multicentre trial of IUDs, 1

TCu220C, 1

T-Cu 380A, 221

Pregnancy and contraception, among young Swedish women, 211

Pregnancy outcome, among young Swedish women, 211

Pregnancy rate,

after removal of Copper T 200, 113

after removal of Nova T, 113

Preimmunization with carrier, effect on antibody response when immunized with

β -hCG coupled to tetanus toxoid (rabbit), 595

Preimplantation embryo, effect of indomethacin-loaded IUD (rat), 97

Progeny, gestation after abortion induced by DL III (baboon), 165

Progesterone + aristolic acid, effect on uterine phosphatase levels during early pregnancy (mouse), 635

Progesterone level,

effect of cadmium chloride (rabbit), 181

effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 457

effect of 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 261

effect of depo-medroxyprogesterone acetate administered on various cycle days, 487

effect of DL III (baboon), 165

effect of ethinyl estradiol + levonorgestrel, 121, 545

effect of levonorgestrel-releasing IUD, 245

effect of medroxyprogesterone acetate, 51

effect of norethisterone oenanthate, 51

effect of vaginal device releasing levonorgestrel, 567

CONTRACEPTION

- Progestogen potencies in oral contraceptives, Delay of Menses Test, 23
- Progestogen-only mini-pills,
 - fertility following discontinuation, 389
 - review of clinical studies, 373
- Prostacyclin release, effect of 2-hydroxyestradiol and estradiol, 317
- Prostaglandin (PG),
 - 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E₂, 261
 - 16-phenoxy- ω -tetranor-prostaglandin E₂-methylsulfonamide, 279
 - prostaglandin E₂, 285
 - 15(S)-15-prostaglandin F_{2 α} methyl ester, 59
- Protein content of uterus, effect of aristolic acid (mouse), 635
- Proteinase inhibitors, antifertility activity (mouse), 137
- Proteolytic enzymes released from leucocytes attached to IUDs, 147
- Randomized multicentre comparative trial, interval IUD insertion in parous women, 1
- Rate of metabolism,
 - medroxyprogesterone acetate, 51
 - norethisterone oenanthate, 51
- Release rate,
 - tranexamic acid from ethylene-vinyl acetate matrix, 521
 - Trasylol from ethylene-vinyl acetate matrix, 521
- Removal,
 - Copper 7, 1
 - Copper T 200, 29
 - IUD use in nulliparous women, 323
 - levonorgestrel-releasing IUD, 245
 - Lippes loop C, 221
 - Lippes Loop D, 1
 - Nova T, 29, 245
 - randomized multicentre trial of IUDs, 1
 - TCu220C, 1
 - T-Cu 380A, 221
- Removal of IUD, return to fertility, 113
- Reproduction and disability, 417
- Retention of silastic IUD, effect of indomethacin incorporation (rat), 159

CONTRACEPTION

- Return of fertility,
 - after removal of IUD, 113
 - effect of DL III (baboon), 165
- Return of menstrual cycle, effect of DL III (baboon), 165
- Return of ovarian activity,
 - medroxyprogesterone acetate, 51
 - norethisterone oenanthate, 51
- Reversal of sterilization, fertility following procedure, 361
- Schistosomiasis, effect of ethinyl estradiol + levonorgestrel in women with active infection, 75
- Second trimester pregnancy termination, administration of Sulprostone, 279
- Selectivity of acrosin inhibitors with respect to fertility (mouse), 137
- Sequential oral contraceptives, fertility following discontinuation, 389
- Serotonin metabolism and depression, effect of ethynodiol diacetate + mestranol, 193
- Serum proteins,
 - effect of antibilharzial and contraceptive drugs (rat), 645
 - effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
 - effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65
 - effect of ethinylestradiol + desogestrel, 229
 - effect of triphasic ethinylestradiol + levonorgestrel, 229
- Sex hormone binding globulin (SHBG),
 - effect of ethinyl estradiol + levonorgestrel, 545
 - effect of ethinylestradiol + desogestrel, 229
 - effect of triphasic ethinylestradiol + levonorgestrel, 229
- Sexuality, fertility and contraception in disabled people, 417
- Sexuality and physical disability, 417
- SHBG (sex hormone binding globulin)
- Side effect,
 - administration of Sulprostone for termination of second trimester pregnancy, 279
 - 9-deoxo-16,16-dimethyl-9-methylene PGE₂ vaginal suppository for termination of early gestation, 261
 - effect of ethinylestradiol + desogestrel, 229
 - effect of levonorgestrel followed by ethinyl estradiol + norgestrel, 41
 - effect of triphasic ethinylestradiol + levonorgestrel, 229
 - 15-ME-PGF₂ α vaginal suppository, 59
 - PGE₂ vaginal suppository for midtrimester pregnancy termination, 285

CONTRACEPTION

- Silastic IUD incorporating indomethacin (rat), 97, 159
- Sperm antibodies, role in subsequent fertility following vasovasostomy, 361
- Spermicide with barrier methods of contraception, effectiveness, 347
- Spontaneous abortion,
 - after sterilization reversal, 361
 - following contraceptive use, 389
- Sterilization,
 - comparative study of culdoscopy and minilaparotomy, 587
 - fertility following reversal, 361
 - use in disabled people, 417
- Subcutaneous implant, fertility following discontinuation, 389
- Sulprostone (16-phenoxy- ω -tetranor-PGE₂-methylsulfonamide)
- Superactive LRH agonist, abortifacient effect, 457
- Surgical contraception, comparative study of culdoscopy and minilaparotomy, 587
- Surgical factors affecting successful reversal of vasectomy, 361
- TCu 200, release of proteolytic enzymes from attached leucocytes, 147
- TCu220C,
 - effect of mineral deposits on copper dissolution rate, 295
 - randomized multicentre comparative trial, 1
- T-Cu 380A, randomized clinical study, 221
- Teratogenesis, following contraceptive use, 389
- Teratogenicity, progestogen-only mini-pill, 373
- Termination,
 - Copper T 200, 29
 - Nova T, 29
- Termination of early gestation, 9-deoxo-16,16-dimethyl-9-methylene PGE₂ vaginal suppository, 261
- Termination of midtrimester pregnancy, PGE₂ vaginal suppository, 285
- Termination of second trimester pregnancy, administration of Sulprostone, 279
- Termination rate,
 - Lippes loop C, 221
 - T-Cu 380A, 221
- Testis cytosolic lactic dehydrogenase-X activity, effect of gossypol (rat), 607
- Testosterone, effect of triphasic ethinylestradiol + l-norgestrel, 505
- Testosterone-estradiol binding globulin, effect of triphasic ethinylestradiol + l-norgestrel, 505

CONTRACEPTION

- Therapeutic abortion, effect on subsequent reproduction, 389
- Therapeutic (safety) index of acrosin inhibitors with respect to fertility (mouse), 137
- Thin and obese women, metabolism of injectable contraceptives, 51
- Thyroxine, effect of triphasic ethinylestradiol + 1-norgestrel, 505
- Time best for insertion, IUD use in nulliparous women, 323
- Tissue distribution in animals, norethisterone, 83
- Tranexamic acid,
 - incorporation into ethylene-vinyl acetate matrix for IUDs, 521
 - release rate from ethylene-vinyl acetate matrix, 521
- Transaminases,
 - effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
 - effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65
- Transcortin,
 - effect of ethinylestradiol + desogestrel, 229
 - effect of triphasic ethinylestradiol + 1-norgestrel, 505
 - effect of triphasic ethinylestradiol + levonorgestrel, 229
- Translocation, IUD use in nulliparous women, 323
- Trasylol,
 - incorporation into ethylene-vinyl acetate matrix for IUDs, 521
 - release rate from ethylene-vinyl acetate matrix, 521
- Trends in use of oral contraceptives, Dutch young women, 205
- Triglycerides,
 - effect of antibilharzial and contraceptive drugs (rat), 645
 - effect of ethinylestradiol + desogestrel, 229
 - effect of triphasic ethinylestradiol + 1-norgestrel, 505
 - effect of triphasic ethinylestradiol + levonorgestrel, 229
- Triphasic oral contraceptive,
 - ethinylestradiol + 1-norgestrel, 505
 - ethinylestradiol + levonorgestrel, 229
- Tryptophan metabolism and correlation to depression, ethynodiol diacetate + mestranol, 193
- Tubal occlusion methods, in relation to reversal of sterilization, 361
- Tubal sterilization, influence on ovarian function, 361
- Uterine activity, effect of piperine (mouse), 625
- Uterine phosphatase levels during early pregnancy, effect of aristolic acid (mouse), 635
- Uterus,
 - effect of aristolic acid (mouse), 635
 - effect of piperine (mouse), 625

- Vaginal device, releasing levonorgestrel, 567
- Vaginal lesions associated with use of cervical caps, 443
- Vaginal ring, fertility following discontinuation, 389
- Vaginal suppository,
 - 9-deoxo-16,16-dimethyl-9-methylene PGE₂ for termination of early gestation, 261
 - 15-ME-PGF₂ α for cervical priming prior to IUD insertion, 59
 - PGE₂ for midtrimester pregnancy termination, 285
- Vasectomy reversal, infertility following vasovasostomy, 361
- Vimule cap,
 - studies of cervical caps, 443
 - vaginal lesions observed with use, 443
- Viral hepatitis, effect of ethinyl estradiol + levonorgestrel on liver function tests and serum proteins in past hepatitis women, 65
- Xanthurenic acid, effect of ethynodiol diacetate + mestranol, 193